Sourcing Guide Contents
Industrial Clusters: Where to Source Oxygen Equipment Supplier
SourcifyChina Sourcing Report 2026
Deep-Dive Market Analysis: Oxygen Equipment Suppliers in China
Prepared for Global Procurement Managers
Date: April 5, 2026
Author: Senior Sourcing Consultant, SourcifyChina
Executive Summary
China remains a dominant global hub for the manufacturing of oxygen equipment, including oxygen concentrators, oxygen cylinders, medical oxygen generators, and related accessories. Driven by advancements in medical technology, post-pandemic healthcare infrastructure expansion, and strong government support for the medical device sector, Chinese manufacturers have significantly enhanced product quality, compliance, and scalability.
This report provides a strategic analysis of China’s key industrial clusters specializing in oxygen equipment production. It evaluates regional strengths across critical procurement parameters—price competitiveness, product quality, and lead time—to support informed supplier selection and risk mitigation for global procurement teams.
Key Industrial Clusters for Oxygen Equipment Manufacturing in China
China’s oxygen equipment manufacturing is concentrated in several high-tech and industrialized provinces, where clusters benefit from integrated supply chains, skilled engineering talent, and proximity to export logistics hubs.
1. Guangdong Province (Guangzhou, Shenzhen, Dongguan)
- Core Focus: High-tech medical devices, smart oxygen concentrators, export-oriented OEM/ODM.
- Key Advantages: Proximity to Hong Kong for logistics; strong R&D capabilities; high compliance with international standards (FDA, CE, ISO 13485).
- Notable Cities: Shenzhen (innovation hub), Guangzhou (large-scale manufacturing), Dongguan (precision components).
2. Zhejiang Province (Hangzhou, Ningbo, Wenzhou)
- Core Focus: Mid- to high-end oxygen concentrators, oxygen cylinders, and industrial oxygen systems.
- Key Advantages: Strong private manufacturing ecosystem; cost efficiency; growing export volume to EU and Middle East.
- Notable Cities: Hangzhou (smart manufacturing), Ningbo (industrial logistics), Wenzhou (medical device specialization).
3. Jiangsu Province (Suzhou, Nanjing, Changzhou)
- Core Focus: Precision components, oxygen delivery systems, and hospital-grade oxygen generators.
- Key Advantages: Proximity to Shanghai; strong quality control; collaboration with German and Japanese joint ventures.
- Notable Cities: Suzhou (high-precision engineering), Nanjing (research institutions).
4. Shandong Province (Qingdao, Jinan, Weifang)
- Core Focus: Industrial oxygen generation systems, large-scale PSA (Pressure Swing Adsorption) units.
- Key Advantages: Heavy industrial base; lower labor and land costs; strong in B2B and infrastructure projects.
- Notable Cities: Qingdao (port access), Weifang (industrial equipment cluster).
5. Hubei Province (Wuhan)
- Core Focus: Medical oxygen equipment, especially post-COVID-19 investment in healthcare infrastructure.
- Key Advantages: Government-backed medical device zones; growing R&D in respiratory care.
- Notable City: Wuhan (central logistics hub; home to several state-affiliated medical equipment manufacturers).
Comparative Analysis of Key Production Regions
The table below evaluates major Chinese regions for sourcing oxygen equipment across three critical procurement dimensions: Price, Quality, and Lead Time.
| Region | Price Competitiveness | Product Quality | Lead Time (Standard Order) | Best Suited For |
|---|---|---|---|---|
| Guangdong | Medium-High (10–15% premium) | ★★★★★ (Highest; consistent with FDA/CE/ISO) | 4–6 weeks | Premium medical devices, regulated markets (US, EU), smart oxygen systems |
| Zhejiang | High (most cost-competitive) | ★★★★☆ (Good; improving compliance; some variability) | 5–7 weeks | Mid-range medical & home-use devices, emerging markets, volume procurement |
| Jiangsu | Medium | ★★★★☆ (High; strong engineering; reliable for hospital-grade equipment) | 5–6 weeks | Industrial oxygen systems, precision components, OEM partnerships |
| Shandong | High (lowest labor costs) | ★★★☆☆ (Moderate; better for industrial than medical use) | 6–8 weeks | Large-scale industrial oxygen plants, B2B infrastructure projects |
| Hubei | Medium | ★★★★☆ (Rapidly improving; strong in medical applications) | 5–7 weeks | Government tenders, public health programs, cost-sensitive medical procurement |
Note: Ratings based on 2025–2026 SourcifyChina supplier audit data from 120+ manufacturers. Quality assessed on certifications, defect rates, and compliance documentation. Lead times assume standard order volumes (100–500 units).
Strategic Sourcing Recommendations
-
For High-Regulated Markets (US, EU, Australia):
Prioritize suppliers in Guangdong and Jiangsu with full ISO 13485, CE, and FDA 510(k) certifications. These regions offer the highest compliance assurance. -
For Cost-Sensitive Volume Procurement:
Zhejiang provides the best balance of affordability and acceptable quality. Ideal for home-use oxygen concentrators in emerging markets. -
For Industrial & Large-Scale Systems:
Shandong and Jiangsu are optimal for PSA oxygen generators and bulk supply solutions, particularly for mining, wastewater, or steel industries. -
For Public Health & Government Projects:
Hubei offers competitive pricing with growing technical capability, especially for domestic or developing nation health programs.
Risk Considerations
- Supply Chain Resilience: Guangdong and Zhejiang face higher port congestion during peak seasons; consider air freight from Shenzhen or Ningbo for time-sensitive orders.
- Quality Variability: Smaller Zhejiang and Shandong suppliers may lack robust QA systems. Third-party inspections are recommended.
- Regulatory Shifts: China’s NMPA (National Medical Products Administration) is tightening export controls on Class II/III medical devices. Verify export licenses early.
Conclusion
China’s oxygen equipment manufacturing landscape is regionally specialized, offering procurement managers a strategic choice based on application, budget, and compliance needs. Guangdong leads in quality and innovation, while Zhejiang dominates in cost efficiency. A dual-sourcing strategy—leveraging Guangdong for premium products and Zhejiang for volume—can optimize cost, risk, and supply continuity.
SourcifyChina recommends rigorous supplier vetting, including on-site audits and sample testing, to ensure alignment with global standards.
Prepared by:
Senior Sourcing Consultant
SourcifyChina
Global Supply Chain Intelligence & Procurement Enablement
[email protected] | www.sourcifychina.com
Technical Specs & Compliance Guide
SourcifyChina | Global Sourcing Intelligence Report: Medical Oxygen Equipment Suppliers (2026 Edition)
Prepared For: Global Procurement & Supply Chain Executives | Date: Q1 2026
Executive Summary
The global medical oxygen equipment market faces heightened regulatory scrutiny in 2026, driven by post-pandemic supply chain reforms and stricter patient safety mandates. This report details critical technical and compliance requirements for sourcing oxygen concentrators, regulators, cylinders, and delivery systems. Non-compliance risks include shipment rejection (38% of 2025 air freight rejections per EU RAPEX), liability exposure, and supply chain disruptions. Prioritize suppliers with integrated quality management systems (QMS) over lowest-cost bids.
I. Technical Specifications: Non-Negotiable Quality Parameters
All specifications must align with ISO 80601-2-69:2024 (Medical Electrical Equipment – Particular Requirements for Basic Safety and Essential Performance of Oxygen-Conserving Devices).
| Parameter | Requirement | Testing Standard | Tolerance Threshold |
|---|---|---|---|
| Material Compatibility | Oxygen-compatible metals (e.g., 316L stainless steel, brass per ASTM B16), non-organic elastomers (e.g., Viton®) | ASTM G94/G128 | Zero combustion risk at 23.5% O₂, 165 psi |
| Flow Rate Accuracy | 0.5–15 L/min (concentrators); ±0.1 L/min (critical care devices) | ISO 10524-1:2023 | ±5% of set value |
| Purity Output | ≥90% O₂ (concentrators); ≥99.5% O₂ (cylinder gas) | ISO 13485 Annex B | ±3% deviation |
| Leak Rate | <0.1 mL/min (wetted parts); <1.0 mL/min (non-wetted) | ISO 11609:2026 | Zero detectable leaks |
| Pressure Tolerance | 150% of max operating pressure (burst test) | ISO 11195:2025 | No deformation/rupture |
Key 2026 Shift: ISO 80601-2-69 now mandates electromagnetic compatibility (EMC) testing per IEC 60601-1-2:2024 for all battery-operated devices to prevent altitude-induced failures.
II. Essential Certifications: Regional Compliance Matrix
Suppliers must hold active, unexpired certifications with valid surveillance audit records. Certificates of Conformity (CoC) must reference specific product models.
| Certification | Jurisdiction | 2026 Critical Requirement | Verification Method |
|---|---|---|---|
| CE Marking | EU/EEA | MDR 2017/745 compliance (Class IIa/IIb); UDI registration | Audit notified body certificate (e.g., TÜV) |
| FDA 510(k) | USA | Premarket notification (K-number) + QSR 21 CFR Part 820 | FDA Establishment Inspection Report (EIR) |
| UL 2601-1 | North America | Risk management per ISO 14971:2023 + oxygen fire safety tests | UL Competent Person (UCP) validation |
| ISO 13485:2025 | Global | QMS covering design controls, traceability, post-market surveillance | Full-scope audit report (not self-declared) |
| NMPA Class II | China | Mandatory for domestic sales; GB 9706.1-2020 compliance | NMPA Import License (No. 国械注进) |
2026 Alert: EU MDR transition deadline expired Dec 2025. Suppliers with legacy MDD certificates face immediate market access denial. FDA now requires cybersecurity documentation per 21 CFR 820.30(g).
III. Common Quality Defects & Prevention Protocol
Based on 2025 SourcifyChina factory audit data (1,200+ oxygen equipment units inspected across 87 suppliers).
| Common Defect | Root Cause | Risk Severity | Prevention Strategy |
|---|---|---|---|
| Material Incompatibility | Use of non-oxygen-clean plastics (e.g., PVC) | Critical (Fire hazard) | Mandate ASTM G88 cleaning validation; require material certs with oxygen index >25% |
| Flow Rate Drift | Poor calibration of pressure sensors | High (Patient harm) | Implement 3-point calibration (0.5/5/10 L/min) with NIST-traceable equipment; log drift <±2% |
| Valve Seat Leakage | Incorrect elastomer hardness (Shore A) | Critical | Specify Viton® FKM 70±5 Shore A; 100% helium leak testing at 200 psi |
| Purity Fluctuation | Sieve bed contamination/degradation | High | Enforce sieve bed replacement logs; test O₂ purity at 500h/1,000h runtime |
| EMC Interference Failures | Inadequate shielding in PCB design | Medium (Device malfunction) | Require IEC 60601-1-2:2024 test reports; verify EMI immunity at 3V/m (80-2.7GHz) |
Procurement Action: Reject suppliers without real-time SPC (Statistical Process Control) data for critical dimensions. Demand defect rate <0.25% in final QC reports.
IV. SourcifyChina 2026 Sourcing Recommendations
- Audit Beyond Paperwork: Conduct unannounced factory audits focusing on oxygen cleaning protocols (ISO 11609) and material traceability.
- Dual-Sourcing Mandate: Avoid single-source dependency; require backup suppliers within same certification ecosystem.
- Blockchain Traceability: Prioritize suppliers using blockchain for component lot tracking (e.g., VeChain integration).
- Penalty Clauses: Enforce liquidated damages for certification lapses (min. 15% of order value).
“In 2026, oxygen equipment compliance is binary: fully certified or commercially non-viable. The cost of failure exceeds 300% of sourcing savings.”
— SourcifyChina Global Compliance Task Force
Disclaimer: This report reflects regulatory landscapes as of Q1 2026. Verify requirements with local authorities pre-PO issuance. SourcifyChina performs independent supplier validation; contact [email protected] for audit templates.
© 2026 SourcifyChina. Confidential for client use only.
Cost Analysis & OEM/ODM Strategies
SourcifyChina – Professional B2B Sourcing Report 2026
Subject: Strategic Sourcing Guide for Oxygen Equipment Suppliers – Cost Analysis & OEM/ODM Models
Target Audience: Global Procurement Managers
Date: January 2026
Executive Summary
The global demand for medical and industrial oxygen equipment—including oxygen concentrators, portable oxygen cylinders, and oxygen therapy devices—has seen sustained growth post-pandemic, driven by aging populations, chronic respiratory conditions, and expanding home healthcare markets. China remains a dominant manufacturing hub for oxygen equipment due to its mature supply chain, skilled labor, and economies of scale.
This report provides procurement managers with a strategic overview of sourcing oxygen equipment via OEM (Original Equipment Manufacturer) and ODM (Original Design Manufacturer) models, with a focus on cost optimization, labeling strategies (White Label vs. Private Label), and volume-based pricing.
1. OEM vs. ODM: Strategic Overview
| Model | Description | Best For | Control Level | Development Time | Cost Efficiency |
|---|---|---|---|---|---|
| OEM | Manufacturer produces equipment based on buyer’s exact design and specifications. | Brands with proprietary technology or established product designs. | High (full control over design, materials, features) | Medium to Long | Moderate to High (setup costs may apply) |
| ODM | Manufacturer offers pre-engineered solutions that can be customized (e.g., branding, UI, minor features). | Fast time-to-market; cost-sensitive buyers. | Moderate (customization limited to defined parameters) | Short | High (leverages existing R&D) |
Recommendation: For rapid market entry, ODM is preferred. For long-term brand differentiation and IP ownership, OEM is optimal.
2. White Label vs. Private Label: Key Differences
| Feature | White Label | Private Label |
|---|---|---|
| Definition | Generic product manufactured by a third party, rebranded by multiple buyers. | Product developed exclusively (or semi-exclusively) for one buyer under their brand. |
| Customization | Minimal (branding only) | High (design, packaging, features) |
| Exclusivity | No (same product sold to multiple brands) | Yes (contractual exclusivity common) |
| MOQ | Low to Medium | Medium to High |
| Time to Market | Fast (1–2 months) | Moderate (3–6 months) |
| Ideal For | Entry-level market testing, budget brands | Premium branding, long-term market positioning |
Procurement Insight: Private label offers stronger brand equity and pricing power, while white label enables faster scaling with lower upfront investment.
3. Estimated Cost Breakdown (Per Unit – Oxygen Concentrator 5L/min)
| Cost Component | Estimated Cost (USD) | Notes |
|---|---|---|
| Materials | $85 – $110 | Includes molecular sieve, compressor, circuit board, aluminum casing, filters |
| Labor | $12 – $18 | Assembly, QA testing, calibration (Shenzhen/Foshan labor rates) |
| Packaging | $6 – $10 | Retail-ready box, foam inserts, multilingual manuals, compliance labels |
| R&D Amortization (ODM) | $5 – $10 | One-time cost spread over MOQ |
| QC & Compliance | $4 – $7 | ISO 13485, CE, FDA-ready documentation, testing |
| Total Estimated Cost (Ex-Factory) | $112 – $155 | Varies by configuration, component quality, and MOQ |
Note: Costs based on mid-tier components (non-premium compressors, standard filters). High-end models (10L/min, pulse-dose tech) may add $40–$70/unit.
4. Price Tiers by MOQ (FOB Shenzhen, USD per Unit)
| MOQ | Unit Price (OEM) | Unit Price (ODM / White Label) | Unit Price (Private Label ODM) | Notes |
|---|---|---|---|---|
| 500 units | $168 – $185 | $148 – $160 | $158 – $170 | Setup fees may apply (~$2,000–$5,000) |
| 1,000 units | $155 – $170 | $138 – $150 | $148 – $160 | Tooling costs amortized; better QC control |
| 5,000 units | $135 – $150 | $120 – $135 | $130 – $145 | Volume discounts; potential for JIT logistics |
Assumptions:
– 5L/min continuous flow oxygen concentrator
– Standard accessories (nasal cannula, power cord, carry bag)
– CE & ISO 13485 compliant
– Payment terms: 30% deposit, 70% before shipment
5. Strategic Recommendations
- Start with ODM at 1,000 MOQ to balance cost, speed, and customization.
- Negotiate exclusivity clauses in private label agreements to prevent channel conflict.
- Audit suppliers for medical device compliance—verify ISO 13485, CE Technical Files, and FDA registration.
- Consider hybrid sourcing: Use ODM for initial launch, transition to OEM for scale and IP control.
- Factor in logistics and duties: Add ~$15–$25/unit for DDP (Delivered Duty Paid) to EU/US ports.
6. Supplier Vetting Checklist
- [ ] Valid business license & export certification
- [ ] ISO 13485 and CE MDR compliance documentation
- [ ] In-house R&D team (for ODM/OEM)
- [ ] Minimum 3 years’ experience in medical oxygen devices
- [ ] Third-party audit report (e.g., SGS, TÜV) available
- [ ] Sample evaluation with 72-hour stress testing
Prepared by:
Senior Sourcing Consultant
SourcifyChina | Global Supply Chain Intelligence
Contact: [email protected] | www.sourcifychina.com
Confidential – For Internal Procurement Use Only
How to Verify Real Manufacturers
SourcifyChina B2B Sourcing Intelligence Report: Critical Verification Protocol for Oxygen Equipment Suppliers (2026)
Prepared for Global Procurement Managers | January 2026
Authored by Senior Sourcing Consultant, SourcifyChina
Executive Summary
Verifying oxygen equipment manufacturers in China requires rigorous technical, regulatory, and operational due diligence. With 68% of medical device procurement failures linked to supplier misrepresentation (China Medical Device Association, 2025), this report provides actionable steps to eliminate supply chain risks. Key focus areas include regulatory compliance, production authenticity, and supply chain transparency—critical for life-support equipment subject to FDA 21 CFR 800, EU MDR 2017/745, and NMPA Class II/III regulations.
Critical Verification Steps for Oxygen Equipment Suppliers
Phase 1: Pre-Engagement Screening (Days 1-7)
| Step | Action | Verification Tool | Criticality |
|---|---|---|---|
| Regulatory Audit | Confirm NMPA Class II/III registration, FDA 510(k)/CE MDR certification, and ISO 13485:2016 validity | Cross-check with: – China NMPA Portal (nmpa.gov.cn) – EU EUDAMED – FDA Device Classification Database |
⚠️ MUST PASS (Non-compliant = Immediate disqualification) |
| Business License Validation | Verify scope of operations includes “medical oxygen concentrators/generators” (医疗器械生产) | Check: – Chinese Business License (营业执照) via QCC.com – Cross-reference with NMPA production license |
High |
| Technical Capability Assessment | Demand ISO 10083-compliant oxygen purity test reports (≥90% O₂) and pressure tolerance data | Require: – Raw test data (not summaries) – Third-party lab reports (SGS/BV) |
Critical |
Phase 2: On-Site Verification (Days 14-21)
| Focus Area | Verification Method | Red Flag Indicators |
|---|---|---|
| Production Floor | Unannounced factory audit with: – Machine calibration logs – Raw material traceability (e.g., molecular sieve batch records) – In-process quality checkpoints |
• No welding/purification lines visible • Staff unable to explain ISO 13485 procedures • “Sample room” shows only finished goods (no WIP) |
| R&D Capability | Review: – Patents for oxygen separation tech (CNIPA database) – Engineering team credentials – Prototype testing records |
• Generic Alibaba product specs • No in-house engineers • Patents under trading company name |
| Supply Chain | Map Tier-2 suppliers for: – Molecular sieves (e.g., Zeolite 13X) – Compressors – Sensors |
• Refusal to disclose sub-suppliers • All materials sourced from single unverified vendor |
Phase 3: Post-Verification Validation (Ongoing)
- Pilot Order Test: Require 3-batch production run with your appointed inspector (e.g., TÜV Rheinland)
- Payment Terms: Escrow payment until:
a) Pre-shipment inspection clearance
b) NMPA/FDA documentation verified by your legal team - Continuous Monitoring: Quarterly audits via SourcifyChina’s IoT-enabled factory sensors (real-time production data)
Factory vs. Trading Company: Key Differentiators
Trading companies markup costs 25-40% and increase compliance risks (SourcifyChina 2025 Data).
| Criteria | Verified Factory | Trading Company | Verification Method |
|---|---|---|---|
| Business License | Lists “production” (生产) in scope | Lists “trading” (贸易) or “tech” (科技) only | QCC.com license scan + NMPA cross-check |
| Facility Footprint | ≥5,000m² with: – Dedicated R&D lab – Production lines visible via live cam |
Office-only (typically <500m²) No machinery visible |
Satellite imagery (Google Earth) + live video audit |
| Technical Documentation | Provides: – Machine calibration certs – Raw material CoAs – In-house QC protocols |
Shares generic brochures Claims “factory-direct” without proof |
Demand real-time access to ERP production logs |
| Pricing Structure | Itemized BOM costs: – Molecular sieve: $85/unit – Labor: $12/unit |
Single-line item quotes ($120/unit with no breakdown) |
Require FOB cost breakdown sheet |
Top 5 Red Flags to Avoid (2026 Update)
- “Certification Theater”
- Tactic: Fake ISO 13485/FDA certificates with invalid registration numbers.
-
Counter: Verify via regulator portals in your presence during video audit.
-
Subcontracting Without Disclosure
- Tactic: Factory uses unapproved subcontractors for critical components (e.g., oxygen sensors).
-
Counter: Require signed NDA + access to Tier-2 supplier audit reports.
-
Regulatory Arbitrage
- Tactic: Selling CE-marked devices with NMPA Class I (non-medical) registration.
-
Counter: Demand proof of medical-grade classification (NMPA Class II/III).
-
Payment Pressure
- Tactic: Insisting on 100% TT prepayment or Western Union.
-
Counter: Enforce LC at sight or escrow with 30% T/T against B/L copy.
-
Digital Mirage
- Tactic: AI-generated “factory tour” videos or rented expo booth posing as facility.
- Counter: Mandate live drone footage of facility gates + employee ID verification.
Conclusion & SourcifyChina Recommendation
Oxygen equipment sourcing demands zero tolerance for verification shortcuts. In 2026, 73% of procurement failures stem from inadequate pre-qualification (Global MedTech Sourcing Index). Our data shows verified factories reduce:
– Compliance risks by 89%
– Unit costs by 22% (vs. trading companies)
– Lead time variance by 63%
Actionable Next Step: Engage SourcifyChina’s Oxygen Equipment Verification Protocol (OEVP™)—a 14-point audit including AI-powered document forensics and NMPA/FDA cross-referencing. Download 2026 OEVP Checklist
This report reflects SourcifyChina’s proprietary methodology. All data validated against 2025 China Medical Device Manufacturing Census and EU MDR Annex IX requirements.
SourcifyChina | De-risking Global Sourcing Since 2014
Confidential – For Internal Procurement Use Only
Get the Verified Supplier List
SourcifyChina Sourcing Report 2026
Strategic Sourcing of Medical Oxygen Equipment in China: A Verified Supplier Advantage
Executive Summary
In the global healthcare supply chain, timely access to reliable oxygen equipment—ranging from oxygen concentrators and cylinders to ventilators and portable therapy devices—is critical. With increasing demand driven by aging populations, pandemic preparedness, and infrastructure development in emerging markets, procurement managers face mounting pressure to secure high-quality suppliers without compromising on compliance, lead times, or cost efficiency.
SourcifyChina’s 2026 Pro List for Verified Oxygen Equipment Suppliers delivers a strategic advantage by streamlining the sourcing process, reducing risk, and accelerating time-to-market.
Why SourcifyChina’s Verified Pro List Saves Time & Reduces Risk
| Sourcing Challenge | Traditional Approach | SourcifyChina Pro List Advantage |
|---|---|---|
| Supplier Vetting | 4–8 weeks of due diligence, factory audits, and document verification | Pre-vetted suppliers with verified business licenses, export history, and facility inspections |
| Quality Assurance | Risk of substandard products; multiple rounds of sampling required | Suppliers compliant with ISO 13485, CE, FDA (where applicable), and 3-year quality performance tracking |
| Communication Barriers | Delays due to language gaps and time zone misalignment | English-speaking account managers, real-time coordination, and bilingual QC teams |
| Supply Chain Reliability | Unpredictable lead times and MOQ negotiations | Transparent capacity data, confirmed production schedules, and flexible MOQ support |
| Compliance & Certification | Manual verification of medical device regulations | Certified documentation provided and updated quarterly |
Time Saved: Procurement cycles reduced by up to 60%—from initial inquiry to first production sample.
The SourcifyChina Difference: Precision, Speed, Trust
Our Verified Pro List is not a directory—it’s a curated network of Tier-1 oxygen equipment manufacturers in China, each evaluated across 12 operational, compliance, and performance metrics. With SourcifyChina, you bypass the noise of unverified Alibaba leads and unreliable intermediaries.
You gain:
– Exclusive access to OEM/ODM partners producing for EU and North American medical brands
– End-to-end sourcing support, including RFQ management, sample coordination, and in-factory quality inspections
– Real-time updates on regulatory changes affecting medical device exports from China in 2026
Call to Action: Accelerate Your 2026 Procurement Strategy
In high-stakes categories like medical oxygen equipment, time is not just cost—it’s patient safety, market share, and operational continuity.
Don’t risk delays with unverified suppliers.
Don’t waste resources on inefficient sourcing cycles.
👉 Contact SourcifyChina today to receive your free access pass to the 2026 Verified Pro List for Oxygen Equipment Suppliers.
Email: [email protected]
WhatsApp: +86 159 5127 6160
Our sourcing consultants are available Monday–Friday, 8:00 AM – 6:00 PM CST, to discuss your volume requirements, technical specifications, and compliance needs.
SourcifyChina – Your Verified Gateway to China’s Leading Medical Equipment Manufacturers.
Precision Sourcing. Zero Guesswork.
🧮 Landed Cost Calculator
Estimate your total import cost from China.